<DOC>
	<DOCNO>NCT00780000</DOCNO>
	<brief_summary>The purpose study determine anti-tumor activity ( via objective response rate ) alvespimycin patient breast cancer previously receive trastuzumab ( except adjuvant therapy ) .</brief_summary>
	<brief_title>Clinical Trial Intravenous Alvespimycin Patients With Her2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>KPS performance status &gt; = 80 % ( `` normal activity effort '' ) Metastatic breast cancer Her2 amplification FISH 3+ Her2 overexpression immunohistochemistry ( `` IHC '' ) Must receive one prior cytotoxic chemotherapy regimen metastatic set Measurable disease RECIST Criteria Received prior lapatinib , investigational ErbB2 and/or investigational EGFR dual tyrosine kinase inhibitor Administration chemotherapy , biological , immunotherapy investigational agent within 14 day prior receipt study medication Pregnant breastfeeding woman . Known CNS metastasis , unless treat without clinically significant neurological deficit Moderately severe dry eye Congestive heart failure , leave ventricular ejection fraction Myocardial infarction active ischemic heart disease within 12 month prior study drug administration Previous malignancy unless free recurrence least 5 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>